Zimmer Biomet beats profit estimates on strong demand for medical devices
Aug 7 (Reuters) -Zimmer Biomet Holdings ZBH.N beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for its devices used in joint reconstruction procedures.
Medical device makers have boosted investor expectations in the recent quarters as more people, especially older Americans, opt for non-urgent surgeries such as hip and knee replacements.
Peer Stryker Corp SYK.N last month raised its annual profit outlook betting on robust demand for its hip and knee implants.
Zimmer, however, cut its annual revenue growth forecast anticipating a higher foreign currency impact. Zimmer now sees revenue growth of 4% to 5% from a year earlier, compared to 4.5% to 5.5% growth forecast previously.
Combined sales at Zimmer's hips and knees units came in at $1.31 billion, shy of analysts' estimate of $1.32 billion, according to LSEG data.
The company also saw strong sales at its unit that sells sports medicine and trauma care products. Sales at the unit rose 6.1% year-over-year to $469.5 million, topping estimates of $465.4 million.
Separately, Zimmer said on Tuesday it would acquire OrthoGrid Systems, a privately held medtech firm to gain access to its artificial intelligence-driven surgical guidance systems for total hip replacement.
The hip and knee implant maker reiterated its full-year 2024 profit expectations in the range of $8.00 to $8.15 per share. Analysts were expecting annual profit of $8.09 per share.
Zimmer's second-quarter revenue rose nearly 4% to $1.94 billion, in-line with analysts' average estimates.
On an adjusted basis, the company posted a profit of $2.01 per share in the quarter ended June 30, topping estimates of $1.99 per share.
Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
